Insybio

02/26/2026

InSyBio will participate in the 9th Technology Transfer Exhibition Patras IQ 2026 (https://patrasiq.gr/) at the Conference and Cultural Centre of the University of Patras from Friday, 27th of February to Sunday, 1st of March 2026.
Come and find us at the exhibition booth of Patras Science Park (2nd floor, stand 52). Our employees Harry Zaverdas, Konstantina Liontou and Foteini Artemis Kiskira would be happy to speak to you about how we revolutionise biomedical data analysis and precision medicine with InSyBio Suite (https://suite.insybio.com/) and InSyBio Diagnostics (https://diagnostics.insybio.com/)!
We are also waiting for everyone at the thematic panel entitled: "The evolution of the research, technology and innovation ecosystem of the Region of Western Greece", on Friday 27/02/2026, 11.00-12.00, at the room Room 2 / II-9. Harry Zaverdas will be representing us along with the other invited companies.

02/26/2026

01/14/2026

🎉 InSyBio team wishes you a happy New Year!

As we welcome 2026, we’re excited to reflect on an extraordinary year of scientific progress, innovative releases, and expanded collaborations here at InSyBio. 2025 was filled with meaningful advancements that strengthened our mission in precision medicine, systems biology, and AI-driven bioinformatics.

✨ Major Highlights from 2025
· Platform Evolution: We launched InSyBio Suite Version 3.4, delivering a major upgrade to the Interact tool for advanced protein interaction analysis and biological network discovery: https://suite.insybio.com/
· Collaborations: Partnering with Syndesis Health (https://syndesis.com/), we demonstrated the enormous value of training AI pipelines for medical applications using highly curated and validated clinical data. This collaboration has led to the development of digital diagnostic tools for cardiovascular diseases: https://diagnostics.insybio.com/
· Scientific Publications: Unravelling the human taste receptor interactome: machine learning and molecular modelling insights into protein-protein interactions. https://www.nature.com/articles/s41538-025-00478-9
· Research: InSyBio is actively participating in research projects focusing on applying its bioinformatics and predictive analysis expertise and technology in various fields, including research on human milk and resolving the molecular mechanisms of bone regeneration.
o GALATEA: https://galateahe.eu/
o OSTEONET: https://osteonethorizon.com/
o REGENERATION: https://regenerationhorizon.eu/
o REPLIFATE: https://replifate.eu/

🤗 Our Thanks:
Thank you to our collaborators, partners, clients, and the global research community. Your engagement and trust fuel our commitment to innovation. As we step into 2026, we look forward to even more discoveries, impactful tools, and collective progress in advancing human health.

Warm wishes for a happy, healthy, and successful New Year!

12/23/2025

🚀 High-Quality Omics Analysis. Fixed Prices. Fast Turnaround.
At InSyBio, we’re launching Fixed-Price Micro-Analysis Services designed to help researchers, biotech companies, and academic groups turn omics data into actionable insights — quickly and transparently.
🧬 Our services include:
RNA-seq Standard Analysis (72h) — $289
RNA-seq Advanced & Multi-modal Integration — $689
Mass Spectrometry Proteomics (Standard & Advanced) — from $312
Biomarker Discovery (Multi-omics, AI/ML & Networks) — $599
ML-ready Data Cleaning & Feature Selection — $299
Grant Data Preparation Packages — $400–$800
✅ Every service includes:
-->1-hour intro call with our expert team
-->Up to 100 omics samples processed
-->Comprehensive analysis report
-->3 months access to results, figures & documentation
Need something custom? We also offer tailored omics analyses based on your project needs.
📩 Contact us: [email protected]

📅 Book a free 30-min consultation:
👉 https://lnkd.in/eNh3zYBj
Let’s turn your data into discoveries. 🔍✨

12/10/2025

12/10/2025

🌟 Highlights from IC3DTH in Vienna! 🌟

We’re delighted to look back on our participation at IC3DTH – The International Conference on 3D Technologies in Hospitals, which took place in Vienna on 28–29 November 2025.

👩‍🔬👩‍💻 Our presenters, and , were on-site showcasing our research poster, featuring key figures and visual snapshots from our latest work:

🔬 “Development of a Domain-Specific Language Model for Bioprocessing and Bone Tissue Engineering”

📊 Poster Highlights Included:

• A visual workflow of the domain-specific language model architecture

• Comparative performance figures vs. general-purpose LLMs

• A data-integration schema for bioprocessing and bone tissue engineering pipelines

• Example outputs demonstrating improved reproducibility and literature-grounded predictions

This work is a major outcome of the OSTEONET 🇪🇺 Marie-Curie Staff Exchange project, which aims to advance 3D in vitro bone tissue models and accelerate innovation in bone-disease research. The project brings together teams from , , , and .

💡 Our domain-specific language model marked an important step forward in integrating AI, bioprocessing, and tissue engineering — enabling smoother data flow, improved reproducibility, enhanced collaboration between computational and experimental groups, and stronger citation-supported bioengineering insights compared with general-purpose LLMs.

We were thrilled to share this work with the vibrant IC3DTH community and to connect with researchers, clinicians, engineers, and innovators pushing the boundaries of biomedical 3D technologies.

🤝✨ A big thank you to everyone who stopped by to meet Ioanna and Alessia during the poster sessions!

11/27/2025

🌟 Exciting Announcement! 🌟

We are proud to share that and will be presenting our latest research at IC3DTH – The International Conference on 3D Technologies in Hospitals - https://www.m3dit.org/m3dit-2025/ , taking place in Vienna on 28-29/11/2025.

🎤 They will showcase our poster on:

🔬 “Development of a Domain-Specific Language Model for Bioprocessing and Bone Tissue Engineering”

This achievement is a key outcome of the OSTEONET 🇪🇺 Marie-Curie Staff Exchange project (https://osteonethorizon.com/), which aims to advance 3D in vitro bone tissue models and accelerate innovation in bone disease research. This is a collaborative work of researchers from InSyBio, 7HC, Industrial Systems Institute / Research Centre ATHENA and Consiglio Nazionale delle Ricerche.

💡Our domain-specific language model represents a step forward in integrating AI, bioprocessing, and tissue engineering, enabling smoother data flow, improved reproducibility, stronger collaboration between computational and experimental teams, and presenting improved and better-supported bioengineering support compared to general-purpose LLM models (ChatGPT and Gemini).

We’re incredibly excited to contribute to the growing ecosystem of AI-enhanced biomedical engineering and to share this vision with the inspiring community at IC3DTH.

Looking forward to connecting with fellow researchers, clinicians, engineers, and innovators! 🤝✨

11/25/2025

👋 Hello, and community!🚀InSyBio Suite Version 3.4 is here!

We’re excited to announce a major upgrade to InSyBio Interact, our advanced tool for protein analysis, protein–protein interaction ( ) exploration, functional annotation, and biological network creation.

With v3.4, researchers can:

🧬Access over 2 million positive and negative PPIs, including the complete interactomes of taste receptors and bone degeneration–related proteins from projects.

🧬Filter interactions using confidence and affinity thresholds and explore 75 computationally derived features with cross-references to major Databases.

🧬Perform in-depth protein analysis, retrieving structural, functional, and regulatory data (GO terms, miRNAs, and interaction partners).

🧬Discover computationally predicted protein complexes via the updated EEMC algorithm, with functional annotations and interactive visualization.

🧬Create and explore custom PPI datasets and full biological networks, all compatible with our interactive module.

💡 Why it matters: InSyBio Interact v3.4 unites high-accuracy PPI prediction, protein exploration, and network biology in a single, user-friendly platform. Researchers can move seamlessly from analyzing a single protein to mapping its role in complex , without the need for any coding expertise.

Read full announcement at: https://insybio.wordpress.com/2025/11/24/insybio-suite-version-3-4-is-announced-introducing-a-major-upgrade-of-the-insybio-interact-tool-for-advanced-protein-interaction-analysis-and-biological-network-discovery/

🎁 Request a free 1-month trial of InSyBio Suite here: https://insybio.com/get-a-free-one-month-license-of-insybio-suite/

InSyBio is thrilled to announce the release of InSyBio Suite Version 3.4, with a major upgrade to the InSyBio Interact tool, an advanced environment for protein analysis, protein–protein interactio…

11/12/2025

There are numerous available plans for patients and the is still rising in USA and EU.

Learn how can help in selecting the most suitable pain alleviation formulation or patch in this 6-minute demonstration of InSyBio's platform for patients.

The proposed solution:
--> Offers a solution for patients and clinicians, allowing personalised recommendations for pain relief by completing a simplified questionnaire in less than 10 minutes.
--> Delivers a solution tested in more than 1500 chronic patients and supported by a series of scientific manuscripts
--> Supports popular and trusted pain alleviation patches (eg, Salonpas and Kailo Patch)
--> 98.1% of the tested participants who were classified as responders to non-opioid treatments presented substantial improvement in all pain metrics after 3-6 months.
--> Allows continuous monitoring of patients and on-the-fly modification of pain alleviation formulation by pain management clinicians

Access for clinicians and patients can be requested at https://diagnostics.insybio.com/

11/11/2025

🔍 New Blog Post by Insybio 's data analyst Harry Zaverdas: Chronic Pain Management in the US & Europe

Chronic pain affects millions, yet care pathways remain fragmented across both regions. Our latest blog explores:

-->Key statistics on prevalence & costs
-->Differences in US vs. European treatment approaches
-->How data-driven, precision pain medicine could transform outcomes

Read the full article 👉 https://insybio.wordpress.com/2025/11/11/chronic-pain-management-in-usa-and-europe-current-status-and-open-challenges/

Chronic Pain presents a major public health crisis and a leading source of human suffering and disability globally. Defined as the pain that persists or recurs for more than 3 months, its prevalenc…